Related Experiment Video
Updated: Aug 14, 2025

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
Inactivation of Mad2B Enhances Apoptosis in Human Cervical Cancer Cell Line upon Cisplatin-Induced DNA Damage
Ju Hwan Kim1, Hak Rim Kim1, Rajnikant Patel2
1Department of Pharmacology, College of Medicine, Dankook University, Cheonan 31116, Republic of Korea.
Abstract:
Mad2B (Mad2L2), the human homolog of the yeast Rev7 protein, is a regulatory subunit of DNA polymerase ζ that shares sequence similarity with the mitotic checkpoint protein Mad2A. Previous studies on Mad2B have concluded that it is a mitotic checkpoint protein that functions by inhibiting the anaphase-promoting complex/cyclosome (APC/C). Here, we demonstrate that Mad2B is activated in response to cisplatin-induced DNA damage. Mad2B co-localizes at nuclear foci with DNA damage markers, such as proliferating cell nuclear antigen and gamma histone H2AX (γ-H2AX), following cisplatin-induced DNA damage. However, unlike Mad2A, the binding of Mad2B to Cdc20 does not inhibit the activity of APC/C in vitro. In contrast to Mad2A, Mad2B does not localize to kinetochores or binds to Cdc20 in spindle assembly checkpoint-activated cells. Loss of the Mad2B protein leads to damaged nuclei following cisplatin-induced DNA damage. Mad2B/Rev7 depletion causes the accumulation of damaged nuclei, thereby accelerating apoptosis in human cancer cells in response to cisplatin-induced DNA damage. Therefore, our results suggest that Mad2B may be a critical modulator of DNA damage response.
Insights
Mad2B, a DNA polymerase ζ subunit, is activated by cisplatin DNA damage, localizing to nuclear foci. Unlike Mad2A, Mad2B does not inhibit APC/C, but its depletion accelerates apoptosis in cancer cells.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- Mad2B (Mad2L2) is a regulatory subunit of DNA polymerase ζ.
- Previous studies suggested Mad2B functions as a mitotic checkpoint protein inhibiting the anaphase-promoting complex/cyclosome (APC/C).
Purpose of the Study:
- To investigate Mad2B's role in DNA damage response.
- To clarify Mad2B's function in relation to DNA damage and APC/C activity.
Main Methods:
- Assessing Mad2B activation and localization following cisplatin treatment.
- Evaluating Mad2B's interaction with Cdc20 and its effect on APC/C activity in vitro.
- Analyzing the consequences of Mad2B depletion on DNA damage and apoptosis in human cancer cells.
Main Results:
- Mad2B is activated by cisplatin-induced DNA damage and co-localizes with DNA damage markers.
- Mad2B binding to Cdc20 does not inhibit APC/C activity in vitro.
- Mad2B does not localize to kinetochores or bind Cdc20 during spindle assembly checkpoint activation.
- Loss of Mad2B leads to increased nuclear damage and accelerated apoptosis in response to cisplatin.
Conclusions:
- Mad2B is not a mitotic checkpoint protein inhibiting APC/C.
- Mad2B plays a critical role in the DNA damage response pathway.
- Mad2B modulation may represent a therapeutic strategy for enhancing cancer treatment efficacy.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
Inhibition of Cdk Activity
Negative Regulator Molecules
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...

